FDA approves Lilly’s small molecule obesity pill Foundayo
New GLP-1 therapy Foundayo is Eli Lilly’s second obesity medicine to be authorised for use in the US.
The US Food and Drug Administration (FDA) has approved Eli Lilly’s small molecule Foundayo (orforglipron) for obesity, offering a new option with potential to shift an increasingly competitive market.
A year ago, Lilly published its latest clinical data on the oral glucagon-like peptide-1 (GLP-1) receptor agonist in obesity, and for those who are overweight with weight-related medical problems.
The FDA’s decision means
Already a member? Sign-in
